세계의 피부과 CRO 시장 : 시장 규모, 점유율 및 동향 분석(유형별, 서비스별, 지역별), 부문별 예측(2025-2033년)

Dermatology CRO Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Preclinical, Clinical), By Service (Clinical Monitoring, Project Management/Clinical Supply Management, Data Management), By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,467,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,890,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,736,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

피부과 CRO 시장 개요

세계 피부과 CRO 시장 규모는 2024년 54억 2,000만 달러로 평가되었습니다. 2033년에는 90억 9,000만 달러에 달하고, 2025-2033년 연평균 5.80% 성장할 것으로 예측됩니다.

피부과용 의약품 개발 수탁기관(CRO) 시장은 건선, 습진, 여드름, 여드름, 피부암 등 만성 피부질환의 전 세계적인 유병률 증가를 배경으로 강력한 성장세를 보이고 있습니다.

또한, 피부과 관련 기업들의 관심 증가와 피부 건강에 대한 인식이 높아지고, 혁신적인 국소 및 전신 치료제의 바이오 의약품 파이프라인이 확대됨에 따라 전문 임상 연구 서비스에 대한 수요가 더욱 증가하고 있습니다. 또한, 피부과 연구개발에 대한 투자 증가, 개인 맞춤형 의료의 채택 증가, 디지털 도구로 촉진되는 환자 참여 강화 등의 요인이 시장 성장을 뒷받침할 것으로 예측됩니다.

또한, 분산형 임상시험, 원격 피부과학, AI를 활용한 피부 영상 진단 등의 새로운 트렌드는 피부과 임상시험의 상황을 재구성하고, 환자 접근성과 데이터 정확도를 향상시키고 있습니다. 웨어러블 피부 센서와 첨단 영상 기술의 사용이 증가하면서 실시간 모니터링과 엔드포인트 평가가 더욱 강화되고 있습니다. 전반적으로 피부과학 연구를 지원하는 정부 이니셔티브 증가, 미용 피부과학 분야의 응용 분야 확대, 아시아태평양 및 라틴아메리카 등 신흥 지역의 임상시험 활동 증가로 인해 시장 시나리오는 양호한 임베디드니다.

또한, CRO는 종합적인 피부과 임상시험 솔루션을 제공하기 위해 지리적 입지 확대, 기술 제공업체와의 제휴, 통합 디지털 플랫폼에 대한 투자 등 전략적 이니셔티브를 취하고 있습니다. 또한, 병변 분석을 위한 AI 및 머신러닝, 분산형 임상시험 플랫폼, 실제 데이터 통합 등의 기술 발전으로 CRO는 임상시험의 효율성, 환자 참여, 데이터 품질을 향상시켜 이 역동적인 시장에서 경쟁력을 강화할 수 있게 되었습니다.

목차

제1장 분석 방법과 범위

제2장 주요 요약

제3장 피부과 CRO 시장 : 변동 요인, 동향 및 범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 가격 모델 분석
• 기술 상황
• 시장 분석 툴
  • Porter의 Five Forces 분석
  • SWOT 분석에 의한 PESTEL
  • COVID-19의 영향 분석

제4장 피부과 CRO 시장 : 유형별 추정 및 동향 분석

• 피부과 CRO 시장 : 부문 대시보드, 유형별
• 피부과 CRO 시장 : 변동 분석, 유형별
• 유형별(2021-2033년)
• Drug Discovery
  • 타겟 검증
  • 리드 식별
  • 리드 최적화
• 전임상
• 임상
  • 제I상
  • 제II상
  • 제III상
  • 제IV상

제5장 피부과 CRO 시장 : 서비스별 추정 및 동향 분석

• 피부과 CRO 시장 : 부문 대시보드, 서비스별
• 피부과 CRO 시장 : 변동 분석, 서비스별
• 서비스별(2021-2033년)
• 프로젝트 관리/임상 공급 관리
• 데이터 관리
• 규제/의료 업무
• 메디컬 라이팅
• 임상 모니터링
• 품질관리/보증
• 생물통계학
• 연구자용 지불
• 연구실
• 환자 및 시설 모집
• 테크놀러지
• 기타

제6장 피부과 CRO 시장 : 지역별 추정 및 동향 분석

• 시장 대시보드 : 지역별
• 시장 점유율 분석 : 지역별(2024년/2033년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 태국
  • 한국
  • 호주
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 시장 진출기업 분류
  • 시장 리더
  • 신흥 기업-
• 기업의 시장 점유율/평가 분석(2024년)
• 기업 개요
  • IQVIA Inc.
  • Labcorp Drug Development
  • Thermo Fisher Scientific Inc.(PPD)
  • Parexel International Corp.
  • Charles River Laboratories
  • ICON, Plc
  • Syneos Health
  • Pharmaron
  • Aragen Life Sciences Ltd.
  • Wuxi AppTec
  • MEDPACE
  • CTI Clinical Trial &Consulting
  • Bioskin
  • Proinnovera GmbH
  • Biorasi, LLC

LSH

영문 목차

영문목차

Dermatology CRO Market Summary

The global dermatology CRO market size was estimated at USD 5.42 billion in 2024 and is projected to reach USD 9.09 billion by 2033, growing at a CAGR of 5.80% from 2025 to 2033. The dermatology contract research organization (CRO) market is experiencing robust growth, primarily driven by the rising prevalence of chronic skin conditions such as psoriasis, eczema, acne, and skin cancers across the globe.

Besides, growing interest of dermatological companies and increasing awareness of dermatological health, coupled with the expansion of the biopharmaceutical pipeline for innovative topical and systemic therapies is further driving the demand for specialized clinical research services. In addition, factors such as growing investments in dermatology R&D, the rising adoption of personalized medicine, and enhanced patient participation facilitated by digital tools are expected to support the market growth.

Moreover, the emerging trends such as decentralized clinical trials, tele dermatology, and AI-powered skin imaging are reshaping the dermatology clinical trial landscape, improving patient access and data accuracy. The increased use of wearable skin sensors and advanced imaging technologies is further enhancing real-time monitoring and endpoint assessment. Overall, the market scenario is favorable due to rising government initiatives supporting dermatology research, expanding applications in cosmetic dermatology, and increased clinical trial activity in emerging regions like Asia-Pacific and Latin America.

Furthermore, the CROs are taking strategic initiatives such as expanding their geographic presence, forming partnerships with technology providers, and investing in integrated digital platforms to offer comprehensive dermatology trial solutions. In addition, technology advancements, including AI and machine learning for lesion analysis, decentralized trial platforms, and the integration of real-world data, enable CROs to enhance trial efficiency, patient engagement, and data quality, strengthening their competitive position in this dynamic market.

Global Dermatology CRO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global dermatology CRO market report based on type, service, and region.

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Discovery
  • Target Validation
  • Lead Identification
  • Lead optimization
• Preclinical
• Clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Project Management/Clinical Supply Management
• Data Management
• Regulatory/Medical Affairs
• Medical Writing
• Clinical Monitoring
• Quality Management/ Assurance
• Bio-statistics
• Investigator Payments
• Laboratory
• Patient and Site Recruitment
• Technology
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Argentina
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Service
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Value-Chain-Based Sizing & Forecasting
  • 1.7.3. Multivariate Model Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Dermatology CRO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Prevalence of Chronic and Complex Skin Disorders
    • 3.2.1.2. Increasing Adoption of Advanced Technologies
    • 3.2.1.3. Growing Demand for Aesthetic Dermatology and Cosmeceuticals
    • 3.2.1.4. Increasing Outsourcing of R&D Activities
    • 3.2.1.5. Favorable Environment for Clinical Trials in Developing Countries
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Quality Issues of CRO Services
    • 3.2.2.2. Intellectual Property Rights Issues
• 3.3. Pricing Model Analysis
• 3.4. Technology Landscape
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Force Analysis
  • 3.5.2. PESTEL by SWOT Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Dermatology CRO Market: Type Estimates & Trend Analysis

• 4.1. Dermatology CRO Market, By Type: Segment Dashboard
• 4.2. Dermatology CRO Market, By Type: Movement Analysis
• 4.3. Dermatology CRO Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
• 4.4. Drug Discovery
  • 4.4.1. Drug Discovery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Target Validation
    • 4.4.2.1. Target Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Lead Identification
    • 4.4.3.1. Lead Identification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Lead Optimization
    • 4.4.4.1. Lead Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Preclinical
  • 4.5.1. Preclinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Clinical
  • 4.6.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Phase I
    • 4.6.2.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Phase II
    • 4.6.3.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.4. Phase III
    • 4.6.4.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.5. Phase IV
    • 4.6.5.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Dermatology CRO Market: Service Estimates & Trend Analysis

• 5.1. Dermatology CRO Market, By Service: Segment Dashboard
• 5.2. Dermatology CRO Market, By Service: Movement Analysis
• 5.3. Dermatology CRO Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 5.4. Project Management/Clinical Supply Management
  • 5.4.1. Project Management/Clinical Supply Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Data Management
  • 5.5.1. Data Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Regulatory/Medical Affairs
  • 5.6.1. Regulatory/Medical Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Medical Writing
  • 5.7.1. Medical Writing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Clinical Monitoring
  • 5.8.1. Clinical Monitoring Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Quality Management/ Assurance
  • 5.9.1. Quality Management/ Assurance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.10. Bio-statistics
  • 5.10.1. Bio-statistics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.11. Investigator Payments
  • 5.11.1. Investigator Payments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.12. Laboratory
  • 5.12.1. Laboratory Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.13. Patient and Site Recruitment
  • 5.13.1. Patient and Site Recruitment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.14. Technology
  • 5.14.1. Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.15. Others
  • 5.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Dermatology CRO Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2033
• 6.3. North America
  • 6.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. U.S
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Competitive Scenario
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Competitive Scenario
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Competitive Scenario
    • 6.3.4.3. Regulatory Framework
    • 6.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Competitive Scenario
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Competitive Scenario
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Competitive Scenario
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Competitive Scenario
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Competitive Scenario
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.7. Denmark
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Competitive Scenario
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.8. Sweden
    • 6.4.8.1. Key Country Dynamics
    • 6.4.8.2. Competitive Scenario
    • 6.4.8.3. Regulatory Framework
    • 6.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key Country Dynamics
    • 6.4.9.2. Competitive Scenario
    • 6.4.9.3. Regulatory Framework
    • 6.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Japan
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. China
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Thailand
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Competitive Scenario
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. South Korea
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Competitive Scenario
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Australia
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Competitive Scenario
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. MEA
  • 6.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
  • 7.1.1. Market Leaders
  • 7.1.2. Emerging Players
• 7.2. Company Market Share/Assessment Analysis, 2024
• 7.3. Company Profiles
  • 7.3.1. IQVIA Inc.
    • 7.3.1.1. Company Overview
    • 7.3.1.2. Financial Performance
    • 7.3.1.3. Service Benchmarking
    • 7.3.1.4. Strategic Initiatives
  • 7.3.2. Labcorp Drug Development
    • 7.3.2.1. Company Overview
    • 7.3.2.2. Financial Performance
    • 7.3.2.3. Service Benchmarking
    • 7.3.2.4. Strategic Initiatives
  • 7.3.3. Thermo Fisher Scientific Inc. (PPD)
    • 7.3.3.1. Company Overview
    • 7.3.3.2. Financial Performance
    • 7.3.3.3. Service Benchmarking
    • 7.3.3.4. Strategic Initiatives
  • 7.3.4. Parexel International Corp.
    • 7.3.4.1. Company Overview
    • 7.3.4.2. Financial Performance
    • 7.3.4.3. Service Benchmarking
    • 7.3.4.4. Strategic Initiatives
  • 7.3.5. Charles River Laboratories
    • 7.3.5.1. Company Overview
    • 7.3.5.2. Financial Performance
    • 7.3.5.3. Service Benchmarking
    • 7.3.5.4. Strategic Initiatives
  • 7.3.6. ICON, Plc
    • 7.3.6.1. Company Overview
    • 7.3.6.2. Financial Performance
    • 7.3.6.3. Service Benchmarking
    • 7.3.6.4. Strategic Initiatives
  • 7.3.7. Syneos Health
    • 7.3.7.1. Company Overview
    • 7.3.7.2. Financial Performance
    • 7.3.7.3. Service Benchmarking
    • 7.3.7.4. Strategic Initiatives
  • 7.3.8. Pharmaron
    • 7.3.8.1. Company Overview
    • 7.3.8.2. Financial Performance
    • 7.3.8.3. Service Benchmarking
    • 7.3.8.4. Strategic Initiatives
  • 7.3.9. Aragen Life Sciences Ltd.
    • 7.3.9.1. Company Overview
    • 7.3.9.2. Financial Performance
    • 7.3.9.3. Service Benchmarking
    • 7.3.9.4. Strategic Initiatives
  • 7.3.10. Wuxi AppTec
    • 7.3.10.1. Company Overview
    • 7.3.10.2. Financial Performance
    • 7.3.10.3. Service Benchmarking
    • 7.3.10.4. Strategic Initiatives
  • 7.3.11. MEDPACE
    • 7.3.11.1. Company Overview
    • 7.3.11.2. Financial Performance
    • 7.3.11.3. Service Benchmarking
    • 7.3.11.4. Strategic Initiatives
  • 7.3.12. CTI Clinical Trial & Consulting
    • 7.3.12.1. Company Overview
    • 7.3.12.2. Financial Performance
    • 7.3.12.3. Service Benchmarking
    • 7.3.12.4. Strategic Initiatives
  • 7.3.13. Bioskin
    • 7.3.13.1. Company Overview
    • 7.3.13.2. Financial Performance
    • 7.3.13.3. Service Benchmarking
    • 7.3.13.4. Strategic Initiatives
  • 7.3.14. Proinnovera GmbH
    • 7.3.14.1. Company Overview
    • 7.3.14.2. Financial Performance
    • 7.3.14.3. Service Benchmarking
    • 7.3.14.4. Strategic Initiatives
  • 7.3.15. Biorasi, LLC
    • 7.3.15.1. Company Overview
    • 7.3.15.2. Financial Performance
    • 7.3.15.3. Service Benchmarking
    • 7.3.15.4. Strategic Initiatives

관련자료